NO20076657L - Kombinasjonsterapi av cancer med AZD2171 og gemcitabin - Google Patents
Kombinasjonsterapi av cancer med AZD2171 og gemcitabinInfo
- Publication number
- NO20076657L NO20076657L NO20076657A NO20076657A NO20076657L NO 20076657 L NO20076657 L NO 20076657L NO 20076657 A NO20076657 A NO 20076657A NO 20076657 A NO20076657 A NO 20076657A NO 20076657 L NO20076657 L NO 20076657L
- Authority
- NO
- Norway
- Prior art keywords
- azd2171
- gemcitabine
- cancer
- human
- combination therapy
- Prior art date
Links
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 title abstract 6
- 229960002412 cediranib Drugs 0.000 title abstract 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title abstract 6
- 229960005277 gemcitabine Drugs 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000005865 ionizing radiation Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0513778A GB0513778D0 (en) | 2005-07-06 | 2005-07-06 | Combination therapy |
| GB0514347A GB0514347D0 (en) | 2005-07-13 | 2005-07-13 | Combination therapy |
| PCT/GB2006/002462 WO2007003933A2 (fr) | 2005-07-06 | 2006-07-03 | Polytherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076657L true NO20076657L (no) | 2008-04-03 |
Family
ID=37005849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076657A NO20076657L (no) | 2005-07-06 | 2007-12-28 | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090176731A1 (fr) |
| EP (1) | EP1901754A2 (fr) |
| JP (1) | JP2009500384A (fr) |
| KR (1) | KR20080031029A (fr) |
| AU (1) | AU2006264620B2 (fr) |
| BR (1) | BRPI0612397A2 (fr) |
| CA (1) | CA2614002A1 (fr) |
| IL (1) | IL188513A0 (fr) |
| MX (1) | MX2007016497A (fr) |
| NO (1) | NO20076657L (fr) |
| NZ (1) | NZ564189A (fr) |
| WO (1) | WO2007003933A2 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| KR20060130764A (ko) * | 2004-03-23 | 2006-12-19 | 아스트라제네카 아베 | 병용 요법 |
| PT1965801E (pt) * | 2005-12-22 | 2011-05-25 | Astrazeneca Ab | Combina??o de azd2171 e pemetrexed |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| KR20060130764A (ko) * | 2004-03-23 | 2006-12-19 | 아스트라제네카 아베 | 병용 요법 |
| CA2569277A1 (fr) * | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Methode de traitement de croissances cellulaires anormales |
| JP2008514576A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法 |
| CN101370519B (zh) * | 2005-12-15 | 2013-07-24 | 阿斯利康(瑞典)有限公司 | 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合 |
| PT1965801E (pt) * | 2005-12-22 | 2011-05-25 | Astrazeneca Ab | Combina??o de azd2171 e pemetrexed |
| WO2008125820A1 (fr) * | 2007-04-13 | 2008-10-23 | Astrazeneca Ab | Polythérapie comprenant de l'azd2171 et de l'azd6244 ou un inhibiteur de mek ii |
-
2006
- 2006-07-03 WO PCT/GB2006/002462 patent/WO2007003933A2/fr not_active Ceased
- 2006-07-03 BR BRPI0612397-0A patent/BRPI0612397A2/pt not_active Application Discontinuation
- 2006-07-03 MX MX2007016497A patent/MX2007016497A/es not_active Application Discontinuation
- 2006-07-03 JP JP2008519988A patent/JP2009500384A/ja active Pending
- 2006-07-03 CA CA002614002A patent/CA2614002A1/fr not_active Abandoned
- 2006-07-03 KR KR1020087002092A patent/KR20080031029A/ko not_active Ceased
- 2006-07-03 US US11/994,824 patent/US20090176731A1/en not_active Abandoned
- 2006-07-03 AU AU2006264620A patent/AU2006264620B2/en not_active Ceased
- 2006-07-03 EP EP06755701A patent/EP1901754A2/fr not_active Withdrawn
- 2006-07-03 NZ NZ564189A patent/NZ564189A/en unknown
-
2007
- 2007-12-28 NO NO20076657A patent/NO20076657L/no not_active Application Discontinuation
- 2007-12-31 IL IL188513A patent/IL188513A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1901754A2 (fr) | 2008-03-26 |
| BRPI0612397A2 (pt) | 2011-02-22 |
| KR20080031029A (ko) | 2008-04-07 |
| AU2006264620A1 (en) | 2007-01-11 |
| CA2614002A1 (fr) | 2007-01-11 |
| IL188513A0 (en) | 2008-08-07 |
| WO2007003933A3 (fr) | 2007-12-27 |
| NZ564189A (en) | 2011-04-29 |
| AU2006264620B2 (en) | 2009-10-22 |
| WO2007003933A2 (fr) | 2007-01-11 |
| US20090176731A1 (en) | 2009-07-09 |
| MX2007016497A (es) | 2008-03-07 |
| JP2009500384A (ja) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| NO20072167L (no) | Kombinasjon omfattende ZD6474 og et antiandrogen | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
| NO20050450L (no) | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft | |
| NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
| BR0309226A (pt) | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
| NO20064753L (no) | Kombinasjonsterapi | |
| NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
| NO20064755L (no) | Kombinasjonsterapi | |
| NO20064754L (no) | Kombinasjonsterapi | |
| NO20056171L (no) | Kombinasjonsterapi | |
| NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |